The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
HIV seropositivity with CD4 counts between 250 and 400 cells/mm3.
Patients with the following symptoms or conditions are excluded:
Known hypersensitivity to hydrolytic enzymes such as Wobenzym.
Known sensitivity to lactose.
Presumption that the patient will not comply with the dosing schedule or follow-up appointments.
Concurrent use of immunosuppressive therapy or steroids.